RVTY Revvity, Inc.
RVTY Revvity, Inc.
Healthcare · Diagnostics & Research
Market read
POC $97.42 · VWAP $98.60 · +17.8% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
1 watchlist
RVTY Price Structure
Loading timeframes…
Peers
Every watchlist RVTY belongs to, members best 30-day change first — RVTY highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech-capital-cycle
Against street estimates
How RVTY's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about RVTY from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 58 days ago · Jun 21 · last pull reported an error, so these may be older than they look
- Revvity (RVTY) Is Down 5.0% After Raising 2026 Outlook And Securing FDA Assay Clearance
- Revvity (NYSE:RVTY) Q1 2026 Earnings Beat Sends Shares Higher Despite Revenue Miss
- Revvity Announces Financial Results for the First Quarter of 2026
- Compared to Estimates, Revvity (RVTY) Q1 Earnings: A Look at Key Metrics
- Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript
RVTY research tape
2 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.